Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas. Homo sapiens
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
assess the efficacy of Pimasertib to characterize its mechanism of action Overall design: GEP analysis of one lymphoma cell line with and without treatment with Pimasertib
创建时间：
2016-01-11
